METHODS FOR OBTAINING SINGLE CELLS AND APPLICATIONS OF SINGLE CELL OMICS
The present application provides methods for obtaining single cells from a sample. Methods for isolating and analyzing molecular features obtained from a single cell are also disclosed herein. For example, individual circulating tumor cells (CTCs) from a sample such as a patient's blood sample can be identified and obtained using methods disclosed herein, and picked for further analysis.
1 . A method for obtaining individual circulating tumor cells (CTCs) in blood, comprising:
providing a blood sample from a patient;
identifying one or more CTCs in the blood sample; and
obtaining single CTCs.
2 . The method of claim 1 , wherein the method comprises lysing non-CTC cells.
3 . The method of claim 2 , wherein the non-CTC cells comprises red blood cells.
4 . The method of claim 1 , wherein said identifying one or more CTCs comprises an immunochemical analysis.
5 . The method of claim 1 , wherein identifying one or more CTCs comprises detecting the expression of at least one tumor-specific marker.
6 . The method of claim 5 , wherein the tumor specific marker is cytokeratin, prostate-specific antigen (PSA), prostate specific membrane antigen (PSMA), mucin- 1 (MUC-1), human epidermal growth factor receptor 2 (HER2), AFP (α-fetoprotein), N-cadherin, epithelial cell adhesion molecule (EpCAM), or carcinoembryonic antigen (CEA).
7 . The method of claim 5 , wherein the tumor specific marker is cytokeratin or EpCAM.
8 . The method of claim 5 , wherein the tumor specific marker is an epithelial cell specific marker.
9 . The method of claim 5 , wherein said identifying one or more CTCs comprises determining the expression of one or more markers that are not expressed in tumor cells.
10 . The method of claim 1 , wherein said identifying one or more CTCs comprises disposing the sample on a solid support.
11 . The method of claim 10 , wherein the solid support is a non-metallic solid support.
12 . The method of claim 10 , wherein the solid support is a glass slide.
13 . The method of claim 10 , wherein said obtaining single CTCs comprises separating the CTCs from the solid support.
14 . The method of claim 13 , wherein said separating the CTCs comprises use of a laser capture microdissection (LCM) system or an automated cell picking device.
15 . The method of claim 13 , wherein said separating the CTC comprises removing a single CTC and the portion of the solid support which the single CTC is attached onto from the solid support.
16 . The method of claim 1 , wherein said obtaining the single CTCs comprises aspiration of a single CTC.
17 . The method of claim 16 , wherein the aspiration is based on hydrostatic force.
18 . The method of claim 16 , wherein the aspiration comprises pipetting.
19 . A method for assessing cancer progression in a patient suffering from cancer, comprising:
providing a circulating tumor cell (CTC) or a substantially pure population of CTCs from the patient; and
performing one or more cellular or molecular analyses on the CTCs to determine cancer progression in the patient.
20 . The method of claim 19 , wherein the substantially pure population of CTCs comprises no more than 20% of non-CTC cells.
21 . The method of claim 19 , wherein the substantially pure population of CTCs comprises no more than 10% of non-CTC cells.
22 . The method of claim 19 , wherein the substantially pure population of CTCs comprises no more than 5% of non-CTC cells.
23 . The method of claim 19 , wherein the cancer is selected from the group consisting of lung cancer, esophageal cancer, bladder cancer, gastric cancer, colon cancer, skin cancer, papillary thyroid carcinoma, colorectal cancer, breast cancer, lymphoma, pancreatic cancer, prostate cancer, ovarian cancer, pelvic cancer, and testicular cancer.
24 . The method of claim 19 , wherein said one or more cellular or molecular analysis comprise morphological analysis, genomics analysis, epigenomics analysis, transcriptomics analysis, proteomics analysis, or any combination thereof.
25 . The method of claim 19 , wherein said one or more cellular or molecular analysis comprise determining one or more DNA mutations in the CTCs.
26 . The method of claim 25 , wherein the DNA mutation comprises an insertion, a deletion, a substitution, a translocation, a gene amplification, or any combination thereof.
27 . The method of claim 25 , wherein the DNA mutation is located in a gene selected from the group consisting of KRAS, BRAF, PTEN, EGFR, ERCC1, RRM1, ELM4, HER2, and ALK.
28 . The method of claim 25 , wherein the DNA mutation is an EML4-ALK fusion or a gene amplification in Her2.
29 . The method of claim 23 , wherein said one or more cellular or molecular analysis comprise determining protein expression level of a cancer specific gene in the CTCs.
30 . The method of claim 23 , wherein said one or more cellular or molecular analysis comprise determining RNA expression level of a cancer specific gene in the CTCs.
31 . The method of claim 29 , wherein the cancer specific gene is cytokeratin, prostate-specific antigen (PSA), prostate specific membrane antigen (PSMA), mucin-1 (MUC-1), human epidermal growth factor receptor 2 (HER2), AFP (α-fetoprotein), N-cadherin, epithelial cell adhesion molecule (EpCAM), epidermal growth factor receptor (EGFR), ERCC1, androgen receptor (AR), human equilibrative nucleoside transporter 1 (hENT1), RRM1, or carcinoembryonic antigen (CEA).
32 . The method of claim 29 , wherein the cancer specific gene is an epithelial mesenchymal transition (EMT) marker or a cancer stem cell (CSC) marker.
33 . The method of claim 32 , wherein the EMT maker is selected from the group consisting of N-cadherin, vimentin, B-catenin (nuclear localized), Snail- 1, Snail-2 (Slug), Twist, EF1/ZEB1, SIP1/ZEB2, and E47.
34 . The method of claim 32 , wherein the CSC marker is CD133 or CD44.
35 . The method of claim 19 , wherein said one or more cellular or molecular analysis comprise whole-genome analysis of the CTCs.
36 . A method for assessing response of a patient suffering from cancer to a treatment, comprising:
providing a circulating tumor cell (CTC) or a substantially pure population of CTCs from the patient; and
performing one or more cellular or molecular analyses to determine treatment response in the patient.
37 . The method of claim 36 , wherein the method the substantially pure population of CTCs comprises no more than 20% of non-CTC cells.
38 . The method of claim 36 , wherein the method the substantially pure population of CTCs comprises no more than 5% of non-CTC cells.